Back

Interleukin-6 predicts cardiovascular events beyond standard modifiable risk factors in individuals without atherosclerotic cardiovascular disease

31 August 2026 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention: biomarkers, inflammation, and cardiac mortality Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Martin Reugels

RWTH University Hospital Aachen, Aachen (Germany)

5 More presentations in this session

Presentation thumbnail
Imaging-derived cardiovascular OrganAge predicts mortality and identifies smoking and diabetes as major accelerators of cardiovascular ageing in UK Biobank
Doctor M. Wamil (Oxford, GB)
Abstract
Presentation thumbnail
Arterial elastance is a heritable and causal vascular endotype of hippocampal atrophy and cognitive decline
Doctor P. Masci (London, GB)
Abstract
Presentation thumbnail
Lipoprotein(a) and cardiovascular–kidney–metabolic syndrome: associations with all-cause mortality and major adverse cardiovascular events in a large population cohort
Mr Q. Tang (Hangzhou, CN)
Abstract
Presentation thumbnail
Higher hs-CRP predicts severe cardiovascular-kidney-metabolic syndrome stages: The NHANES 2015 – 2018 survey cycle
Doctor D. Corsi (New Brunswick, US)
Abstract
Presentation thumbnail
The impact of inflammatory and cholesterol risk on cardiovascular events among statin-treated individuals: an observational study using UK Biobank data
Doctor D. Niederseer (Davos Wolfgang, CH)
Abstract

Access the full session

Session thumbnail
Risk factors and prevention: biomarkers, inflammation, and cardiac mortality

The Event

Event poster

ESC Congress 2026

31 August 2026 11:05 CET
You may be interested in
thumbnail
Congress Presentation
Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab
1 September 2019
thumbnail
Congress Presentation
Cardiovascular risk assessment in multiple myeloma patients undergoing carfilzomib therapy: a new risk prediction model for cardiovascular adverse events
12 December 2020
thumbnail
Congress Presentation
Prediction of cardiovascular outcomes by subtle changes in the peripheral immune cell landscape - insights from the LURIC single cell RNA-sequencing study (LuRNA)
30 August 2024
thumbnail
Congress Presentation
Interleukin-6 receptor gene polymorphism (rs2228145) in patients with hypertrophic cardiomyopathy.
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources